TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer
| Autor: | Robert T. Jones, Evan P. Hass, Qiong Zhou, Sébastien Rinaldetti, Simon R.V. Knott, Thomas R. Cech, Molishree Joshi, Dan Theodorescu, Bassem Ben Cheikh, Neeraj Agarwal, Daniel V. LaBarbera |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
TRIM28
Transcription Genetic Cell Survival cells Mutant mTORC1 Tripartite Motif-Containing Protein 28 Gene Expression Regulation Enzymologic TRIM24 Transcription (biology) Cell Line Tumor Humans Telomerase reverse transcriptase Promoter Regions Genetic Telomerase neoplasms Cell Proliferation Multidisciplinary Cell growth Chemistry Stem Cells Cell sorting Gene Expression Regulation Neoplastic enzymes and coenzymes (carbohydrates) Urinary Bladder Neoplasms Mutation embryonic structures Cancer research biological phenomena cell phenomena and immunity Transcription Factors |
| Zdroj: | Proceedings of the National Academy of Sciences. 118 |
| ISSN: | 1091-6490 0027-8424 |
| DOI: | 10.1073/pnas.2102423118 |
| Popis: | Bladder cancer (BC) has a 70% telomerase reverse transcriptase (TERT or hTERT in humans) promoter mutation prevalence, commonly at -124 base pairs, and this is associated with increased hTERT expression and poor patient prognosis. We inserted a green fluorescent protein (GFP) tag in the mutant hTERT promoter allele to create BC cells expressing an hTERT-GFP fusion protein. These cells were used in a fluorescence-activated cell sorting-based pooled CRISPR-Cas9 Kinome knockout genetic screen to identify tripartite motif containing 28 (TRIM28) and TRIM24 as regulators of hTERT expression. TRIM28 activates, while TRIM24 suppresses, hTERT transcription from the mutated promoter allele. TRIM28 is recruited to the mutant promoter where it interacts with TRIM24, which inhibits its activity. Phosphorylation of TRIM28 through the mTOR complex 1 (mTORC1) releases it from TRIM24 and induces hTERT transcription. TRIM28 expression promotes in vitro and in vivo BC cell growth and stratifies BC patient outcome. mTORC1 inhibition with rapamycin analog Ridaforolimus suppresses TRIM28 phosphorylation, hTERT expression, and cell viability. This study may lead to hTERT-directed cancer therapies with reduced effects on normal progenitor cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|